(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 6.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.87%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.08%.
Anaptysbio's revenue in 2026 is $234,603,000.On average, 13 Wall Street analysts forecast ANAB's revenue for 2026 to be $4,321,725,174, with the lowest ANAB revenue forecast at $3,735,835,737, and the highest ANAB revenue forecast at $5,041,006,514. On average, 13 Wall Street analysts forecast ANAB's revenue for 2027 to be $6,126,253,141, with the lowest ANAB revenue forecast at $4,969,710,842, and the highest ANAB revenue forecast at $7,123,817,589.
In 2028, ANAB is forecast to generate $8,231,200,372 in revenue, with the lowest revenue forecast at $6,330,653,234 and the highest revenue forecast at $11,212,681,898.